SCHEMBL4032441

SCHEMBL4032441

Oc1ccc(-c2n[nH]c3cc(Cl)ccc23)cc1

nearest known ligand 0.75

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.75
HSP90AB1 P08238 1/20 0.75
FGFR1 P11362 8/20 0.73
FGFR2 P21802 5/20 0.73
FGFR3 P22607 2/20 0.73
MAP2K4 P45985 8/20 0.68
MAPK1 P28482 4/20 0.54
MAPK6 Q16659 4/20 0.54
MAPKAPK2 P49137 3/20 0.54
MAPKAPK3 Q16644 2/20 0.54
MAPKAPK5 Q8IW41 1/20 0.54
ESR1 P03372 1/20 0.53
CHEK1 O14757 2/20 0.49
CDK4 P11802 1/20 0.45
CCNA2 P20248 1/20 0.45
CCND1 P24385 1/20 0.45
CDK2 P24941 1/20 0.45
CCND3 P30281 1/20 0.45
KDR P35968 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4032487 0.84 MAP2K4 (0.61) PDPK1HSP90AB1FGFR1FGFR2FGFR3
SCHEMBL14738828 0.84 MAP2K4 (0.63) PDPK1HSP90AB1FGFR1FGFR2FGFR3
SCHEMBL9271850 0.83 MAP2K4 (0.64) PDPK1HSP90AB1FGFR1FGFR2FGFR3
SCHEMBL22801745 0.81 MAP2K4 (1.00) PDPK1HSP90AB1FGFR1FGFR2FGFR3
SCHEMBL22819380 0.80 MAP2K4 (0.63) PDPK1HSP90AB1FGFR1FGFR2FGFR3
SCHEMBL22801611 0.77 MAP2K4 (1.00) PDPK1HSP90AB1MAP2K4MAPK1MAPK6
SCHEMBL2955244 0.77 MAP2K4 (0.55) PDPK1HSP90AB1FGFR1FGFR2FGFR3
SCHEMBL4030030 0.76 PDPK1 (0.59) PDPK1HSP90AB1FGFR1FGFR2FGFR3
SCHEMBL4027845 0.76 MAP2K4 (0.78) PDPK1HSP90AB1FGFR1FGFR2FGFR3
SCHEMBL1513050 0.76 PDPK1 (0.80) PDPK1HSP90AB1FGFR1FGFR2FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols WYETH (US) 2007-09-27 US claimed
US-7241791-B2 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2007-07-10 US claimed
CN-1321984-C Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation WYETH CORP (US) 2007-06-20 CN claimed
US-20060111421-A1 Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors WYETH (US) 2006-05-25 US claimed
CN-1692102-A Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation WYETH CORP (US) 2005-11-02 CN claimed
EP-1542976-A1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES Wyeth (US) 2005-06-22 EP claimed
US-20040167127-A1 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2004-08-26 US claimed
WO-2004031159-A1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH (US) 2004-04-15 WO claimed
EP-1542976-B1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH CORP (US) 2009-02-04 EP disclosed
CN-101054364-A Substituted 4-(indazol-3-yl)phenols as estrogen receptor (ER) ligands and their use in the treatmentof inflammarory diseases WYETH CORP (US) 2007-10-17 CN disclosed
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols WYETH (US) 2007-09-27 US disclosed
US-7241791-B2 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2007-07-10 US disclosed
CN-1321984-C Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation WYETH CORP (US) 2007-06-20 CN disclosed
CN-1692102-A Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation WYETH CORP (US) 2005-11-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols INSR, TNNI3, INSRR PDPK1 2941/4885HSP90AB1 2737/4885FGFR1 419/4885
US-20040167127-A1 Substituted 4-(indazol-3-yl)phenols INSR, MSR1, TNNI3 PDPK1 2152/4885HSP90AB1 2322/4885FGFR1 450/4885
US-20060111421-A1 Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors IKBKB, NFKBIA, IKBKG PDPK1 605/4885HSP90AB1 927/4885FGFR1 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.